Biodesix, Inc.
BDSXHealthcareNASDAQDiagnostics & Research
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Biodesix, Inc. focuses on Diagnostics & Research services and products. Biodesix, Inc. operates as a diagnostic solutions company. Valued at $276.2M, BDSX is a micro-cap name in its sector. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.
Market Cap
$276.2M
Beta
0.59
P/E (TTM)
—
P/E (Fwd)
-119.00
EPS (TTM)
$-3.10
EPS (Fwd)
$-0.22
ROE
-540.0%
ROA
-14.1%
Cash
$30.0M
Total Debt
$71.8M
Free CF
-$10.9M
52W Change
182.1%
Annual Financials
Cash vs Debt
Where BDSX stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, BDSX finished 58.83% above its 150-day moving average ($17.10) and 83.64% above its 200-day moving average ($14.79). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BDSX overbought or oversold?
At the September 3, 2026 close, BDSX's RSI(14) was 57.3, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, BDSX has $30.0M in cash with $71.8M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow is running at -$10.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -540.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $38.2M (2022) to $88.5M (2025), reflecting a 132% increase over the period.
BDSX's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing BDSX.